One Case of Rhabdomyolysis Induced by Levofloxacin-atorvastatin Drug-drug Interaction

Chinese Journal of Pharmacovigilance ›› 2019, Vol. 16 ›› Issue (5): 315-317.

One Case of Rhabdomyolysis Induced by Levofloxacin-atorvastatin Drug-drug Interaction

ZHOU Changkai¹, GAO Jing², XING Xiaomin¹, GUO Qie¹, CUI Xueyan³, FENG Lifang¹, SHI Shiqiang¹, ZHANG Rui¹, CHENG Shaoyuan¹, CUI Mengna¹, SHANG Xiuling¹, CONG Yue¹, JING Fanbo^1,*

1 The Affiliated Hospital of Qingdao University, Shandong Qingdao 266100, China;
2 The Third People's Hospital of Qingdao, Shandong Qingdao 266041, China;
3 Qianfoshan Hospital of Shandong Province, Shandong Jinan 250013, China

Received:2018-11-05 Revised:2019-06-11 Online:2019-05-20 Published:2019-06-11

Abstract

CLC Number:

R994.11

ZHOU Changkai, GAO Jing, XING Xiaomin, GUO Qie, CUI Xueyan, FENG Lifang, SHI Shiqiang, ZHANG Rui, CHENG Shaoyuan, CUI Mengna, SHANG Xiuling, CONG Yue, JING Fanbo. One Case of Rhabdomyolysis Induced by Levofloxacin-atorvastatin Drug-drug Interaction[J]. Chinese Journal of Pharmacovigilance, 2019, 16(5): 315-317.

References

[1] Bywaters E G,Beall D.Crush injuries with impairment of renalfunction. 1941[J]. J Am Soc Nephrol,1998,9(2):322-332.
[2] Law M,Rudnicka A R.Statin safety: a systematic review[J]. Am J Cardiol,2006,97(8A): 52C-60C.
[3] 张亮, 张向荣, 周秋云, 等.左氧氟沙星注射液致肌酸激酶升高1例[J].中国药物警戒, 2018, 15(1) :57-58.
[4] Radcliffe K A, Campbell W W.Statin myopathy[J].Curr Neurol Neurosci Rep, 2008, 8(1) :66-72.
[5] Ishiguro N,Senda C,Kishimoto W,et al.Identification of CYP3A4 as the predominant isoform responsible for the metabolism of ambroxol in human liver microsomes[J]. Xenobiotica,2000,30(1):71-80.
[6] Kashida Y,Kato M.Toxic effects of quinolone antibacterial agents on the musculoskeletal system in juvenile rats[J]. Toxicologic Pathology,1997,25(6):635-643.
[7] Korzets A,Gafter U,Dicker D,et al.Levofloxacin and rhabdomyolysis in a renal transplant patien[J]. Nephrology Dialysis Transplant-ation,2006,21(11):3304-3305.
[8] Czock D,Hüsig-Linde C,Langhoff A,et al.Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis[J]. Clinical Journal of the American Society of Nephrology,2006,1(6):1263-1268.
[9] Akamine Y,Yasui-Furukori N,Uno T.Drug-drug interactions of P-gp substrates unrelated to CYP metabolism[J]. Curr Drug Metab,2018,19(14):1-6.
[10] Zakeri-Milani P,Valizadeh H.Intestinal transporters:enhanced absorption through P-glycoprotein-related drug interactions[J]. Expert Opin Drug Metab Toxicol,2014,10(6):859-871.
[11] Shumaker A C,Bullard H M,Churpek J,et al.Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein[J]. J Oncol Pharm Pract,2018,0(0):1-4.
[12] Pal D,Mitra A K.MDR-and CYP3A4-mediated drug-drug interactions[J]. Journal of Neuroimmune Pharmacology,2006,1(3):323-339.

[1]	SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131.
[2]	ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136.
[3]	BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140.
[4]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[5]	LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
[6]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[7]	ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
[8]	WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
[9]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[10]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[11]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[12]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[13]	LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
[14]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[15]	ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.